Drug Development Inputs & Services Stocks Q2 Recap: Benchmarking Medpace (NASDAQ:MEDP)
2 Mid-Cap Stocks Worth Your Attention and 1 We Question
NEW YORK , Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Medpace Holdings, Inc. (NASDAQ: MEDP)...
3 High-Flying Stocks with Solid Fundamentals
3 Cash-Heavy Stocks on Our Watchlist
2 Momentum Stocks with Exciting Potential and 1 We Question
Why Is Medpace (MEDP) Stock Soaring Today
Medpace (NASDAQ:MEDP) Exceeds Q2 CY2026 Expectations, Stock Jumps 18.6%
Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%. ...